5 Stocks to Watch: Week of 5/5/2025

May the Fourth be with you! To prep for the week ahead, we’ve created a top-notch list of stocks with stellar near-term prospects:

• AudioEye (NASDAQ: AEYE) could see triple-digit upside in the coming year 
• 8x8 (NASDAQ: EGHT) is a penny stock with strong potential 
• Why analysts are loving Boston Scientific (NYSE: BSX) right now
• Pediatrix Medical Group (NYSE: MD) enjoys strong implied upside from the smart money crowd
• Triple Flag Precious Metals (NYSE: TFPM) has stunning growth potential 
• Plus, a bonus STRONG SELL selection

Let’s get to it! (Did you miss last week’s picks? Get ‘em here.)

1- Triple Flag Precious Metals Corp (NYSE: TFPM)

Triple Flag is a precious metals streaming business — in essence, it makes agreements with producers to purchase all of their output upfront at a discount. This allows it to operate an efficient, asset-light model that generates plenty of high-margin recurring cash flow tied to long-life assets, and it could allow you to gain exposure to the ongoing precious metals boom in a unique way.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $20.58 — get current quote > 

Max 1-year forecast: $26.00 

Why we’re watching:

• TFPM has flown relatively under the radar thus far — the stock is currently covered by just 2 analysts, and has 1 Strong Buy rating and 1 Buy rating. See the ratings
• However, quantity isn’t everything when it comes to coverage — there’s also the issue of quality to consider. Both of the aforementioned analysts are quite highly rated.
• Jefferies’ researcher Matthew Murphy (a top 11% rated analyst) doubled down on a Strong Buy rating on April 22, and increased his price target from $24 to a Street-high $26.
• Murphy attributed their price target hike to the announcement that Triple Flag Precious Metals will purchase Orogen Royalties for $304M, or C$2.00 per Orogen share.
• It is "early days at Expanded Silicon," the analyst said, with production after 2029, but aspects of the deal Jefferies "definitely" likes include the fact that the operator is a major, namely AngloGold, it is in a "top tier jurisdiction" (Nevada), and the full participation royalty structure.
• On April 14, ScotiaBank’s Tanya Jakusconek (a top 10% rated analyst) maintained a prior Buy rating, and hiked her price target from $21 to $23.
• TFPM has a Zen Rating of A. Only the top 5% of equities, based on a holistic analysis of 115 proprietary factors, qualify for the highest grade. To be more precise, Triple Flag Precious Metals stock currently ranks in the 97th percentile overall.
• TFPM shares rank highly in three categories. In terms of Growth, they rank in the top 4% of equities. Moreover, they rank in the top 7% according to Momentum and Artificial Intelligence, indicating the presence of a strong uptrend confirmed by the findings of a neural network trained on more than 20 years of fundamental and technical data. (See all 7 Zen Component Grades here >)

2- 8x8 (NASDAQ: EGHT) 

8x8 provides a unified cloud-based communication and contact center platform geared toward enterprises and mid-sized businesses. Although Wall Street is highly divided in terms of sentiment when it comes to EGHT, it has recently received a vote of confidence from a highly-rated analyst — and it also merits high marks from our rating system.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $1.80 — get current quote > 

Max 1-year forecast: $3.50 

Why we’re watching:

• Opinions are quite divided regarding 8x8. The stock currently has 6 analyst ratings — 2 Strong Sells, 1 Sell, 1 Hold, 1 Buy, and 1 Strong Buy. See the ratings
• With that being said, the average 12-month price forecast for EGHT shares currently stands at $2.43, which implies a 33.68% upside.  
• Rosenblatt researcher Catharine Trebnick (a top 7% rated analyst) doubled down on a Strong Buy rating on April 24, while cutting her price target from $3.30 to $2.70.   
• Our proprietary rating system seems to agree with Trebnick rather than dissenting opinions. In fact, EGHT stock carries the highest possible Zen Rating, A, and currently ranks in the 99th percentile of all the equities that we track.
• Moreover, EGHT is currently the 3rd highest rated stock in the entire App industry.
• For a better sense of its specific strengths, we have to take a closer look at 8x8’s Component Grade ratings. The stock ranks in the top 3% according to Value, the top 4% according to Growth, and the top 10% in terms of Safety. (See all 7 Zen Component Grades here >)

3- AudioEye (NASDAQ: AEYE) 

AudioEye is in the business of making digital content more accessible. To be precise, the company offers a platform that helps businesses of all sizes create content that meets standards such as ADA and WCAG through a mix of human expert testing, automation, and artificial intelligence. Beyond simply helping businesses stay compliant with regulations, AudioEye also helps content reach broader audiences, and Wall Street is quite bullish regarding the company’s future prospects.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $11.12 — get current quote > 

Max 1-year forecast: $35.00 

Why we’re watching:

• At present, AEYE stock has 4 analyst ratings — split evenly between Strong Buys and Buys. See the ratings  
• Zach Cummins of B. Riley Securities (a top 9% rated analyst) recently maintained a Strong Buy rating, but cut his 12-month price forecast for AudioEye shares from $26 to $20.
• Cummins revised his coverage in front of the company’s Q1 2025 earnings on April 29. Cummins explained that they cut their price target to reflect the compression in peer valuation multiples in recent weeks.
• In a preview note, Cummins told readers to expect consensus-meeting results from the name. The analyst conceded, however, that investors "will be more focused on the management's FY 2025 guidance in the context of the slowing macro environment.
• AEYE currently has an overall Zen Rating of B — and stocks with this distinction have provided an average annual return of 19.88% since the early 2000s. Moreover, AudioEye currently ranks in the top 9% of the more than 4,600 stocks that we track.
• Growth is the strongest of AudioEye’s Component Grade ratings, as it ranks in the top 2% of equities in this regard. (See all 7 Zen Component Grades here >)

4- Pediatrix Medical Group (NYSE: MD)

Our next entry is a healthcare provider that focuses on services geared toward newborns, children, and expectant mothers in the U.S. and Puerto Rico. While Pediatrix Medical Group hasn’t earned the full-fledged support of Wall Street (at least yet), our system has identified it as a strong performer in multiple key categories — and the busines looks set to continue a rather strong winning streak in place since early 2024.

Zen Rating: A (Strong Buy)  — see full analysis >  

Recent Price: $12.77 — get current quote > 

Max 1-year forecast: $18.50 

Why we’re watching:

• At present, 6 analysts issue ratings for MD stock, which has 1 Strong Buy rating, 1 Buy rating, and 4 Hold ratings. That might not sound promising at first — but keep reading, there’s more than meets the eye here. See the ratings
• For one, the average price target for Pediatrix shares currently stands at $16.75 — a figure that implies a hefty 36.73% upside from current prices. 
• In addition, MD is currently the highest-rated stock in the entire Medical Care Facility industry.
• In 2024, the company delivered an EPS beat of at least 10% each quarter — so there’s a bit of a winning streak going on.
• Pediatrix shares currently rank in the 99th percentile of equities and carry an overall Zen Rating of A.
• In fact, the company’s Component Grade ratings are incredibly well-rounded. Pediatrix stock ranks in the top 5% according to Sentiment, the top 8% in terms of Value, the top 10% in terms of Safety and Financials, and the top 11% in terms of Growth. (See all 7 Zen Component Grades here >)

5- Boston Scientific (NYSE: BSX)

Boston Scientific produces a very wide variety of medical devices, from run-of-the-mill pacemakers to advanced stents and brain stimulation systems. BSX is one of the most widely-covered and respected biotech names on Wall Street — and for good reason. Plenty of analysts have revised their coverage following the company’s recent earnings call — and they see plenty of upside to come.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $102.71  — get current quote > 

Max 1-year forecast: $130.00 

Why we’re watching:

• BSX enjoys broad support from Wall Street, with 12 Strong Buy ratings, 4 Buy ratings, and no Hold, Sell, or Strong Sell ratings. See the ratings
• Truist Securities researcher Richard Newitter (a top 5% rated analyst) recently doubled down on a Strong Buy rating, and increased his 12-month price forecast from $113 to $117.
• The analyst’s revised outlook came after Boston Scientific’s Q1 2025 report. Newitter said the "impressive" quarter delivered revenue and margin outperformance, and noted that management's guidance is absorbing the 2H 2025 tariff impact.
• In fact, Q1 marked the ninth consecutive quarter in which Boston Scientific delivered an earnings per share (EPS) beat.
• BSX shares currently have a Zen Rating of B, and rank in the top 7% of the more than 4,600 equities that we track. Stocks in this class have provided an average annual return of 19.88% since the early 2000s.
• Boston Scientific stock has two key strengths — the first is the fact that it ranks in the top 3% of stocks according to Sentiment. A total of 6 analysts have revised their coverage following the Q1 report — all of them have maintained Buy or Strong Buy ratings, and all of them have increased their price targets.
• BSX also ranks in the top 3% of equities in terms of its Artificial Intelligence Component Grade rating, indicating that a neural network trained on more than 20 years of fundamental and technical data has picked up on subtle signs that hint at future outperformance. (See all 7 Zen Component Grades here >)

STRONG SELL: First Citizens BancShares (NASDAQ: FCNCA)

Despite enjoying widespread support from analysts, FCNCA is faced with several headwinds that might not be readily apparent. The stock ranks near the very bottom of our rating system, and average forecasts predict both earnings and revenue contraction, with incredibly weak growth prospects that could easily see the bank overshadowed by more resilient competitors.

Zen Rating: F (Strong Sell) — see full analysis >  

Recent Price: $1,773 — get current quote > 

Max 1-year forecast: $2,700 

Why we’re watching:

• There’s an interesting disparity at play here — 8 analysts issue ratings for FCNCA stock, which currently has 5 Strong Buy ratings, 1 Buy rating, and 2 Hold ratings. In spite of that, there’s reason to believe that it will struggle going forward. See the ratings.
• The most recent coverage from a top-rated analyst came from Goldman Sachs’ Ryan Nash (a top 17% rated analyst), who maintained a Strong Buy rating but cut his price target from $2,535 to $2,200.
• Despite Nash’s vote of confidence, First Citizens BancShares currently ranks in the bottom 4% of the stocks tracked by our system.
• FCNCA is ranked the 289th stock out of a total of 295 in the Bank industry.
• First Citizens BancShares stock has an overall Zen Rating of F, and ranks in the bottom 1% of stocks on the whole.
• The stock’s Growth Component Grade rating is the key culprit here — as it ranks in the bottom 1% according to this category. Earnings are forecast to contract by 12.25% per year, while revenues are expected to shrink by 4.58% per year. Lastly, the business is forecast to generate much lower returns on assets, at 1.17%, compared to the industry average of 13.26%. (See all 7 Zen Component Grades here >)

What to Do Next?

• 200 Stocks to Sell Now >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.